logo
Share SHARE
FONT-SIZE Plus   Neg

Dell Special Committee Urges Stockholders To Reject Icahn's Proposal

A Special Committee of the Board of Dell Inc. (DELL) Tuesday recommended its shareholders to reject Carl Icahn's proposal for a $15.6 billion self-tender by the company at $14 per share.

"Based on analyses prepared by our advisors and our own view of the business, we do not believe that Icahn's proposal is superior to the certainty of value offered by a sale of the entire Company at $13.65 per share, " said the committee.

The committee believes that it is unwise to layer substantial financial risk on a company already facing significant challenges from competition and from the rapid pace of technological change.

As a private company controlled by Dell and Silver Lake, the company will have a significant debt burden, the risks of that capital structure will be borne entirely by the buyers and not by the public stockholders.

According to the committee, Icahn's proposal does not provide the basis for it to change its recommendation. The Board could independently resolve to consummate various leveraged recapitalization transactions.

The company also warned its shareholders of Icahn's campaign to discredit the Special Committee and accuse it of frightening Dell stockholders, and has urged the stockholders to base their decision on the facts without being misled by Icahn's self-serving accusations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT